Dovonex Psoriasis 50 microgram/g ointment *

  • Company:

    LEO Pharma
  • Status:

    No Recent Update
  • Legal Category:

    Supply through pharmacy only
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 06 July 2020

File name

ie-mockup-pl dovonex psoriasis excip_1594025427.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 06 July 2020

File name

ie-spc clean dovonex psoriasis_1594024816.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

- In section 2 the quantity of propylene glycol has been added

- In section 4.8 the reporting of side effects statement has been updated in accordance with the latest version of Annex 5

Updated on 13 February 2020

File name

ie-pl-dovonex psoriasis ointment-paraffin_1581590509.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision
  • Addition of information on alternative format leaflets

Updated on 07 December 2016

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 5.1 and 10 updated as follows;


5.1      
Pharmacodynamic properties

ATC Code: D05A X02

Pharmacotherapeutic group: Other antipsoriatics for topical use

Calcipotriol is a vitamin D derivative.  In vitro data suggest that calcipotriol induces differentiation and suppresses proliferation of keratinocytes.  This is the proposed basis for its effect in psoriasis. A clinical improvement usually starts to become apparent after two weeks’ treatment.

 

10        DATE OF REVISION OF THE TEXT

April 2016 December 2016

Updated on 07 December 2016

Reasons for updating

  • New SPC for new product

Legal category:Supply through pharmacy only

Updated on 27 June 2016

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision

Updated on 27 June 2016

File name

PIL_16733_458.pdf

Reasons for updating

  • New PIL for new product

Updated on 17 May 2016

Reasons for updating

  • New SPC for new product

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

None provided

Updated on 13 May 2016

Reasons for updating

  • New PIL for new product